Updates on incidence, mortality and survival of liver cancer using Korea central cancer registry database: 1999-2022

利用韩国中央癌症登记数据库更新1999-2022年肝癌的发病率、死亡率和生存率

阅读:1

Abstract

BACKGROUNDS/AIMS: Liver cancer (LC) remains a major contributor to morbidity and mortality globally. This study seeks to provide updated insights into the epidemiological trends of LC in South Korea by examining changes in incidence, mortality, and survival rates between 1999 and 2022, with the goal of guiding public health interventions and informing clinical decision-making. METHODS: This retrospective cohort study utilized data from Korea Central Cancer Registry (KCCR) for primary LC cases, classified as code C22 according to the International Classification of Diseases, tenth version (ICD-10), diagnosed from 1999 to 2022. Crude rates and age-standardized rates (ASRs) were determined. Additionally, subgroup analyses were conducted separately for hepatocellular carcinoma (HCC, C22.0) and intrahepatic cholangiocarcinoma (IHCC, C22.1). RESULTS: Between 1999 and 2022, both the incidence and mortality rates of HCC showed marked decreases. The annual percent change of ASR for incidence and mortality was -2.99% and -4.89%, respectively. There was a notable rise in 5-year survival rates for HCC, especially among patients with localized-stage disease. Conversely, IHCC incidence stabilized and mortality rates showed minimal change. Although patients with localized IHCC achieved significantly higher survival rates following surgical resection, only a small proportion of IHCC cases were diagnosed at a localized stage (22.4%). CONCLUSIONS: Analysis of LC trends in Korea reveals a persistent reduction in incidence and significant improvements in early detection and survival rates for HCC. Despite these gains, IHCC continues to pose clinical difficulties, underscoring the need for further studies to enhance early diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。